{
    "nctId": "NCT00475956",
    "briefTitle": "Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours",
    "officialTitle": "Phase I, Open-Label Study To Assess the Safety, Tolerability and Pharmacokinetics of Daily Oral Doses of Cediranib (RECENTIN\u2122;AZD2171) (20, 30 or 45mg) When Co-Administered With Daily Oral Doses of AZD0530 (125mg or 175mg) in Patients With Advanced Solid Tumours",
    "overallStatus": "COMPLETED",
    "conditions": "Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Determine the safety and tolerability of ascending daily oral doses of AZD2171 when co-administered with AZD0530 to patients with advanced solid tumours by assessment of AEs, vital signs, HRCT Scans, clin chem, haematology, urinalysis, ECG and phys exam",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written consent\n* Cancer diagnosis \\& stage\n* Patients for whom no standard therapy exists\n* World Health Organization (WHO) performance status 0-2\n* One or more measurable lesions\n\nExclusion Criteria:\n\n* Prostate cancer\n* Untreated unstable brain or meningeal metastases\n* Specific laboratory ranges\n* Pregnant or breast-feeding women\n* Any evidence of severe or uncontrolled diseases\n* Participation in other trials within 30 days",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}